These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 25204804

  • 1. A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer.
    Fan P, Agboke FA, Cunliffe HE, Ramos P, Jordan VC.
    Eur J Cancer; 2014 Nov; 50(16):2866-76. PubMed ID: 25204804
    [Abstract] [Full Text] [Related]

  • 2. Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells.
    Fan P, Cunliffe HE, Griffith OL, Agboke FA, Ramos P, Gray JW, Jordan VC.
    Eur J Cancer; 2014 Nov; 50(16):2877-86. PubMed ID: 25212499
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells.
    Fan P, Agboke FA, McDaniel RE, Sweeney EE, Zou X, Creswell K, Jordan VC.
    Eur J Cancer; 2014 Jan; 50(2):457-68. PubMed ID: 24183378
    [Abstract] [Full Text] [Related]

  • 4. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM, Kuba MG, Miller TW, Davies BR, Arteaga CL.
    Breast Cancer Res; 2013 Jan; 15(4):R55. PubMed ID: 23844554
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.
    J Natl Cancer Inst; 2004 Jun 16; 96(12):926-35. PubMed ID: 15199112
    [Abstract] [Full Text] [Related]

  • 6. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
    Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI.
    Endocr Relat Cancer; 2005 Jul 16; 12 Suppl 1():S99-S111. PubMed ID: 16113104
    [Abstract] [Full Text] [Related]

  • 7. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling.
    Martin LA, Pancholi S, Chan CM, Farmer I, Kimberley C, Dowsett M, Johnston SR.
    Endocr Relat Cancer; 2005 Dec 16; 12(4):1017-36. PubMed ID: 16322340
    [Abstract] [Full Text] [Related]

  • 8. erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines.
    Knowlden JM, Gee JM, Barrow D, Robertson JF, Ellis IO, Nicholson RI, Hutcheson IR.
    Breast Cancer Res; 2011 Sep 22; 13(5):R93. PubMed ID: 21939528
    [Abstract] [Full Text] [Related]

  • 9. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D, Dardes R, Liu H, MacGregor-Schafer J, Zapf J, Jordan V.
    Endocrinology; 2001 Feb 22; 142(2):838-46. PubMed ID: 11159857
    [Abstract] [Full Text] [Related]

  • 10. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
    Kruger DT, Alexi X, Opdam M, Schuurman K, Voorwerk L, Sanders J, van der Noort V, Boven E, Zwart W, Linn SC.
    Int J Cancer; 2020 Apr 15; 146(8):2348-2359. PubMed ID: 31490549
    [Abstract] [Full Text] [Related]

  • 11. Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations.
    Fan P, Craig Jordan V.
    Steroids; 2014 Nov 15; 90():44-52. PubMed ID: 24930824
    [Abstract] [Full Text] [Related]

  • 12. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
    Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R.
    Cancer Res; 2008 Feb 01; 68(3):826-33. PubMed ID: 18245484
    [Abstract] [Full Text] [Related]

  • 13. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
    Gaddy VT, Barrett JT, Delk JN, Kallab AM, Porter AG, Schoenlein PV.
    Clin Cancer Res; 2004 Aug 01; 10(15):5215-25. PubMed ID: 15297425
    [Abstract] [Full Text] [Related]

  • 14. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Ribas R, Pancholi S, Rani A, Schuster E, Guest SK, Nikitorowicz-Buniak J, Simigdala N, Thornhill A, Avogadri-Connors F, Cutler RE, Lalani AS, Dowsett M, Johnston SR, Martin LA.
    Breast Cancer Res; 2018 Jun 08; 20(1):44. PubMed ID: 29880014
    [Abstract] [Full Text] [Related]

  • 15. Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance.
    Pitta CA, Papageorgis P, Charalambous C, Constantinou AI.
    Cancer Lett; 2013 Sep 01; 337(2):167-76. PubMed ID: 23752064
    [Abstract] [Full Text] [Related]

  • 16. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
    Fan P, McDaniel RE, Kim HR, Clagett D, Haddad B, Jordan VC.
    Eur J Cancer; 2012 Dec 01; 48(18):3488-98. PubMed ID: 22658320
    [Abstract] [Full Text] [Related]

  • 17. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue.
    Chong YM, Colston K, Jiang WG, Sharma AK, Mokbel K.
    Breast Cancer Res Treat; 2006 Oct 01; 99(3):275-88. PubMed ID: 16752221
    [Abstract] [Full Text] [Related]

  • 18. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
    Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, Liu S, González-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CL.
    Cancer Res; 2011 Nov 01; 71(21):6773-84. PubMed ID: 21908557
    [Abstract] [Full Text] [Related]

  • 19. Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo.
    Liu XF, Bagchi MK.
    J Biol Chem; 2004 Apr 09; 279(15):15050-8. PubMed ID: 14722073
    [Abstract] [Full Text] [Related]

  • 20. Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim.
    Periyasamy-Thandavan S, Takhar S, Singer A, Dohn MR, Jackson WH, Welborn AE, LeRoith D, Marrero M, Thangaraju M, Huang S, Schoenlein PV.
    Breast Cancer Res; 2012 Mar 19; 14(2):R52. PubMed ID: 22429491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.